New blood test aims to sharpen prostate cancer detection

NCT ID NCT07543757

Recruiting now Diagnosis Sponsor: Sequenom, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study is testing a blood test called Proclarix to see if it can better identify men with aggressive prostate cancer before they have a biopsy. About 500 men aged 40-75 with certain PSA levels will give a blood sample before their scheduled biopsy. The test results will be compared to the biopsy findings to see how accurate it is at ruling out serious cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER DETECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER DETECTION

Contacts and locations

Locations

Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Chesapeake Urology Associates
RECRUITING

Hanover, Maryland, 21076, United States
Chesapeake Urology Associates
RECRUITING

Towson, Maryland, 21204, United States
Crystal Run Healthcare
RECRUITING

Middletown, New York, 10941, United States
Graves Gilbert Clinic
RECRUITING

Bowling Green, Kentucky, 42101, United States
Idaho Urologic Institute
RECRUITING

Meridian, Idaho, 83642, United States